论文部分内容阅读
目的 探讨C-erbB_2、C-myc和EGFR多种癌基因共扩增与人体非小细胞肺癌的复发、转移和预后的相关性。方法 采用DNA印迹技术(Blot)分别检测156例非小细胞肺癌手术标本及正常肺组织DNA中C-erbB_2、C-myc和EGFR基团扩增现象,并对上述所检测的患者作5年随访追踪以观察多种癌基因扩增与肺癌患者预后的相关性。结果C-erbB_2、C-myc和EGFR基因中出现双基因以上的共扩增率与肺癌的TNM分期呈正相关,Ⅰ期患者的共扩增率为46%,Ⅱ~Ⅲ期肺癌患者的阳性共扩增率为64%(P＞0.05)。多种癌基因共扩增呈阴性的肺癌患者生存率高于呈阳性患者,两组间具有明显差异(P=0.001)。多种癌基因共扩增率与肺癌的组织学类型、性别和年龄无相关性(P＞0.05)。结论 C-erbB_2、C-myc和EGFR多基因共扩增率与非小细胞肺癌患者的复发、转移和生存期相关。
Objective To investigate the relationship between the co-amplification of multiple oncogenes of C-erbB_2, C-myc and EGFR and the recurrence, metastasis and prognosis of human non-small cell lung cancer. METHODS: The amplification of C-erbB_2, C-myc, and EGFR in DNA of 156 NSCLC specimens and normal lung tissues was detected by Southern blotting (Blot). Five-year follow-ups were performed on these patients. Follow-up to observe the correlation of multiple oncogene amplifications with the prognosis of lung cancer patients. Results The co-amplification rate of two genes in C-erbB_2, C-myc, and EGFR genes was positively correlated with the TNM stage of lung cancer. The co-amplification rate was 46% in patients with stage I and positive in stage II-III lung cancer patients. The amplification rate was 64% (P>0.05). The survival rate of lung cancer patients with negative co-amplification of multiple oncogenes was higher than that of positive patients, with significant differences between the two groups (P=0.001). There was no correlation between co-amplification rates of multiple oncogenes and histological types, gender and age of lung cancer (P>0.05). Conclusion The co-amplification rate of C-erbB_2, C-myc and EGFR multigenes is related to the recurrence, metastasis and survival of NSCLC patients.